Loading the company…
Loading the company…
Privately held: no public financials. Families: Cholecystectomy & appendectomy, Skin substitutes & wound grafts, Bone graft & orthobiologics, Lumbar fusion.
All companies · Product and company coverage
In 2025, Arthrex reported engagement with 90 surgeons and other clinicians in the states MedaRep covers, worth $259K in consulting, speaking, meals and travel for its device products, the most in Rhode Island ($53K to 2). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Rhode Island ($53K, 2 engaged), Michigan ($28K, 5 engaged), New Jersey ($27K, 4 engaged), Florida ($17K, 14 engaged), Alabama ($17K, 2 engaged).
In the last ten years FDA made 137 decisions for Arthrex (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 4 procedure families, the most in 2020 (20). The latest was on 2026-09-25.
| Family | Decisions on record |
|---|---|
| Cholecystectomy & appendectomy | 9 |
| Skin substitutes & wound grafts | 2 |
| Bone graft & orthobiologics | 1 |
| Lumbar fusion | 1 |
| Arthrex FiberButton |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Arthrex.